Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): Results of a phase 1 dose-escalation study

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4569-4578

  Costa, Rogério A ^a,b   Jorge, Rodrigo ^b   Calucci, Daniela ^a   Cardillo, José A ^a   Melo Jr , Luiz A S ^a   Scott, Ingrid U ^c  

^a Hospital de Olhos de Araraquara   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; CIPROFLOXACIN; TROPICAMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ABNORMAL VISION; ABRASION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA ABRASION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; HYPEREMIA; INJECTION SITE PAIN; MALE; OCULAR PRURITUS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS DISEASE; VITREOUS FLOATERS; VITREOUS PROLAPSE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; IMMUNOLOGY; INJECTION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33750575485     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0433     Document Type: Article

References (23)

1. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173.
2. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187.
3. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP report (published correction in Arch Ophthalmol 2000;118:488). Arch Ophthalmol. 1999;117:1329-1345.
4. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol. 1991;109:1242-1257.
5. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration; results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
6. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report no. 2. Arch Ophthalmol. 2001;119:198-207.
7. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. VIP report no. 2. Am J Ophthalmol. 2001;131:541-560.
8. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes. TAP report no. 3. Arch Ophthalmol. 2002;120:1443-1454.
9. Rubin GS, Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) study group. Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) investigation. TAP report no 4. Retina. 2002;22:536-544.
10. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials. TAP report no. 5. Arch Ophthalmol. 2002;120:1307-1314.
11. Bessler NM and the VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients (published correction in Retina. 2004;24:990). Retina 2004;24:512-520.
12. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysls of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. Retina. 2004;24:1-12.
13. Kaiser PK; Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP Report no. 8. Graefes Arch Clin Exp Ophthalmol. Published online March 15, 2006.
14. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
16. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
17. Muller YA, Chen Y, Christinger HW, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4-a resolution and mutational analysis of the interface. Structure. 1998;6:1153-1167.
18. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-881.
19. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
20. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
21. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. Published online February 13, 2006
22. Genenteeh: Press Releases-News Release February 28, 2006. Available at: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id= 9427. Accessed March, 2006.
23. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.